Vitamin D and Cardiovascular Risk in Hyperuricemia Patients

483 patients with hyperuricemia were stratified by vitamin D status to investigate its combined effect on cardiovascular disease risk. The dataset includes demographic, lifestyle, and detailed clinical laboratory parameters, including cardiac biomarkers like troponin I and BNP. Data were collected from a single hospital in China between September 2023 and November 2024.

Use Cases

• Assessing the correlation between serum 25-hydroxyvitamin D levels and cardiovascular biomarkers (e.g., cTnI, BNP) in a hyperuricemic cohort.
• Modeling cardiovascular disease risk based on combined demographic (age, BMI), lifestyle (smoking), and clinical laboratory (lipids, glucose) factors.
• Stratifying patient risk groups using defined clinical cutoffs for vitamin D deficiency, insufficiency, and sufficiency.

Strengths

• Contains detailed, de-identified clinical data for 483 patients, a substantial sample for a focused clinical study.
• Includes a wide range of validated clinical measures, from basic vitals (blood pressure) to specific cardiac biomarkers (cTnI, BNP).
• Patients are clearly stratified into three clinically defined vitamin D status groups (n=150, 226, 107) based on serum concentrations.

Limitations

• The dataset's row count is not explicitly confirmed; the 483 patient count is from the description, but the 'rows' field is listed as 'unknown' or 'None'.
• As a single-center, cross-sectional study, findings may not be generalizable and cannot establish causality.
• Limited metadata on specific column names and data dictionary details beyond the high-level variable categories listed.

Provenance

Source

Second Affiliated Hospital of Harbin Medical University.

Collection Method

De-identified clinical data from a cross-sectional study of admitted patients.

Time Range

01/09/2023 to 01/11/2024.

Freshness

Last updated on 2026-03-20 according to platform metadata.

Geography

Harbin, China (inferred from hospital location).